## AvMed

## **MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\***

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; fax to 1-877-535-1391. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. If information provided is not complete, correct, or legible, authorization can be delayed.

**For Medicare Members:** Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <u>https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx</u>. Additional indications may be covered at the discretion of the health plan.

## Drug Requested: Aliqopa<sup>®</sup> (copanlisib) IV (J9999/C9399) (Medical)

### MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name:	
Member AvMed #:	Date of Birth:
Prescriber Name:	
Prescriber Signature:	Date:
Office Contact Name:	
	Fax Number:
NPI #:	
DRUG INFORMATION: Authoriz	ration may be delayed if incomplete.
Drug Name/Form/Strength:	
	Length of Therapy:
Diagnosis:	ICD Code, if applicable:
Weight (if applicable):	Date weight obtained:

# \*Dosage will be approved for 60mg administered as an intravenous infusion on Days 1, 8, and 15 of a 28 day cycle.\*

□ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

(Continued on next page)

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

□ Member is age 18 years or older

### AND

□ Prescribing physician is an oncologist or hematologist

#### AND

Member has a diagnosis of relapsed follicular lymphoma, defined as having received at least two prior systemic therapies

Medication being provided by: Please check applicable box below.

Location/site of drug administration: \_\_\_\_\_\_

NPI or DEA # of administering location:

### <u>OR</u>

**D** Specialty Pharmacy – Proprium Rx

For urgent reviews: Practitioner should call AvMed Pre-Authorization Department if they believe a standard review would subject the member to adverse health consequences. AvMed's definition of urgent is a lack of treatment that could seriously jeopardize the life or health of the member or the member's ability to regain maximum function.

\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\* \*<u>Previous therapies will be verified through pharmacy paid claims or submitted chart notes.</u>\*